查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029烟碱酰胺嘌呤二核甘酸的全球市场
市场调查报告书
商品编码
1169029

2022-2029烟碱酰胺嘌呤二核甘酸的全球市场

Global Nicotinamide Adenine Dinucleotide Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 96 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

烟碱酰胺嘌呤二核甘酸是一种□啶核甘酸，是细胞的重要辅□和底物，包括 DNA 修復、表观遗传基因调控、细胞内钙信号传导和免疫功能。 它由两个核甘酸、一个腺嘌呤碱基和一个烟□胺碱基组成。 NAD 通常由两种类型的核甘酸组成，即腺嘌呤碱基和烟□胺碱基。 NAD通常以氧化型和还原型两种形式存在，简称NAD+和NADH。 NAD也可以作为一种重要的辅助抗衰老药物。 现代生物学研究中最着名的NAD补充剂是NADH，一种延长细胞生命週期（抗衰老）的线粒体激素。 NAD+ 还主要用于糖酵解等分解代谢途径，分解能量分子以产生 ATP。 所有活细胞在其呼吸过程中都使用辅□烟碱酰胺嘌呤二核甘酸 (NAD)。

在预测期内 (2022-2029)，全球烟碱酰胺嘌呤二核甘酸市场预计将以 11.25% 的复合年增长率增长。

市场动态：消费者对 NAD 健康意识的提高推动了市场扩张

NAD 的使用让人们更容易在正确的时间睡觉和吃饭，从而推动市场增长。 此外，世界各地人们可支配收入的增加正在带来生活方式的改变。 结果，快餐变得更受欢迎。 结果，垃圾食品的消费量增加，导致体内胆固醇水平失衡。 这可能会增加对该药物的需求，并推动烟碱酰胺嘌呤二核甘酸 (NAD) 市场的增长。 NAD 也可以由烟酸和色氨酸产生。 另一方面，NAD 可用于治疗大多数癌症。 因此，全球心血管疾病患病率的增加将导致对烟碱酰胺嘌呤二核甘酸（NAD）的需求增加，从而推动烟碱酰胺嘌呤二核甘酸（NAD）市场的增长。

但是，旨在防止不利健康影响的政府剂量法规预计会限制行业增长。

市场细分：全球烟碱酰胺嘌呤二核甘酸市场份额最高的是食品级

食品级类别占据了最高的销售份额，预计将保持这一地位。 由于 NAD 的抗氧化特性，其在食品和饮料行业的使用已显着扩大，增加了对食品级 NAD 的需求。 NAD 作为许多重要生物过程的底物和辅助因子发挥着重要作用，例如 DNA 修復和表观遗传调控基因表达，并有望进一步推动市场。

另一方面，预计医药品类在预测期内将大幅扩张。 NAD 作为生产众多保健药物的活性成分的流行增加了製药公司对 NAD 的需求。 由于 NAD 增强药物在修復 DNA 损伤和修饰以预防阿尔茨海默病、痴呆和帕金森氏病等疾病方面的效率，预计製药行业对 NAD 的需求量很大。

地理渗透：亚太地区将在预测期内占据主导地位

由于 NAD 在营养品和补充剂製造中的广泛适用性及其在製药领域的日益普及，亚太地区可能会成为该行业的重要枢纽。 此外，对改进慢性病疫苗接种的需求不断增加以及市场参与者的强大存在被推测将刺激该地区的市场增长。 预计北美将在 2021 年占据重要的市场收入份额。 消费者对健康益处的认识不断提高是帮助推动该地区市场增长的关键因素。 此外，该地区心血管疾病的增加将创造对 NAD 的需求。

内容

第1章调查方法及范围

  • 调查方法
  • 市场范围

第2章主要趋势与发展

第 3 章执行摘要

  • 按等级划分的市场细分
  • 按应用划分的市场细分
  • 按地区划分的市场细分

第4章市场动态

  • 市场影响因素
    • 司机
    • 约束因素
    • 商机
  • 影响分析

第5章行业分析

  • 波特的五力分析
  • 价值链分析
  • 专利分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措

第 7 章按等级

  • 食品级
  • 医药级
  • 其他

第八章应用

  • 膳食补充剂
  • 医药
  • 其他

第9章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 意大利
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第10章竞争格局

  • 竞争场景
  • 竞争战略分析
  • 市场情况/份额分析
  • 併购分析

第11章公司简介

  • Bontac 生物工程
    • 公司概况
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Hefei Home Sunshine Pharmaceutical Technology Co., Ltd.
  • F. Hoffmann-La Roche Ltd
  • HiMedia Laboratories
  • NutriScience Innovations, LLC
  • Nutrifoods
  • Bontac Bio-engineering（shenzhen）co., ltd
  • Krackeler Scientific
  • Shandong Lankang Bio-Technology Co., Ltd.
  • Shenzhen Hygieia Biotechnology Co., Ltd

第12章 DataM

简介目录
Product Code: DMFB6040

Market Overview

The pyridine nucleotide nicotinamide adenine dinucleotide (NAD+) is a critical cofactor and substrate for several essential cellular processes, including DNA repair, epigenetically modulated gene expression, intracellular calcium signaling, and immunological functions. As suggested by its name, it comprises two nucleotides, one with an adenine base and the other with a nicotinamide base. Their shared phosphate groups bind them together. NAD generally comes in two forms: oxidized and reduced, denoted by NAD + and NADH abbreviations. NAD can also be used as a critical supplemental anti-aging medication. One of the most well-known NAD supplements in contemporary biological research is NADH, a mitochondrial hormone that lengthens cells' life cycles (anti-aging). NAD + is also primarily used in catabolic pathways, such as glycolysis, which breaks down energy molecules to create ATP. All living cells use the coenzyme nicotinamide adenine dinucleotide for their respiratory processes (NAD).

The global nicotinamide adenine dinucleotide market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 11.25 % during the forecast period (2022-2029)

Market Dynamics: Increasing consumers health awareness towards NAD drives market expansion

The market's growth is fueled by the use of NAD, making it easier to sleep and eat at the proper times. Additionally, the rise in disposable income among people around the world has brought about lifestyle changes. This has increased the popularity of fast food. As a result, increased consumption of junk food has brought an imbalance in the body's cholesterol levels. This will probably increase the demand for medications and fuel the growth of the Nicotinamide Adenine Dinucleotide (NAD) market. NAD can also be produced from nicotinic acid or tryptophan. On the other hand, NAD can be used to treat most cancers. Therefore, the demand for nicotinamide adenine dinucleotide (NAD) will rise as the prevalence of cardiovascular diseases increases globally, fueling the growth of the nicotinamide adenine dinucleotide (NAD) market.

However, government dosage regulations intended to prevent adverse health effects are predicted to limit industry growth.

Market Segmentation: Food grade segment accounted for the highest share in global nicotinamide adenine dinucleotide market

The highest revenue share was taken by the food grade category, and it is anticipated that it will hold that position for the anticipated amount of time. Because of NAD's antioxidant properties, its use in the food and beverage industry has grown significantly, which has raised the demand for NAD of the food grade. It is anticipated that NAD's significant role as a substrate and cofactor for numerous vital biological processes, including DNA repair and epigenetically controlled gene expression, will further drive the market.

On the other hand, over the forecast period, the pharmaceuticals category is expected to expand significantly. The popularity of NAD as an active ingredient in the production of numerous health medications has increased demand for NAD among pharmaceutical companies. There is anticipated to be a sizable demand for NAD in the pharmaceutical industry due to the efficiency of NAD-boosting medications in repairing DNA damage and modifications to prevent diseases like Alzheimer's disease, dementia, and Parkinson's disease.

Geographical Penetration: Asia Pacific is the dominating region during the forecast period

Asia Pacific region may emerge as a major hub for this industry owing to the wide applicability of NAD in manufacturing nutrition and supplementation together with its growing adoption in the pharma sector. Additionally, increasing demand for improving immunization to chronic diseases, along with the strong presence of market players, is estimated to stimulate regional market growth. North America is expected to hold a significant market revenue share in the year 2021. Growing awareness related to the health benefits among the consumer is the key factor that helps in boosting the market growth in the region. In addition, a growing number of cardiovascular diseases in the region will create a demand for the NAD.

Competitive Landscape:

There are several established participants in the industry and local manufacturers; hence, the market is fragmented. The nicotinamide adenine dinucleotide industry is expected to see several product innovation initiatives, strategic partnerships, mergers, and acquisitions by industry participants. Some of the key players in the industry are Bontac Bioengineering, Hefei Home Sunshine Pharmaceutical Technology Co., Ltd., F. Hoffmann-La Roche Ltd, HiMedia Laboratories, NutriScience Innovations, LLC, Nutrifoods, Bontac Bio-engineering(shenzhen)co., ltd, Krackeler Scientific, Shandong Lankang Bio-Technology Co., Ltd, and Shenzhen Hygieia Biotechnology Co., Ltd. For instance, On December 7, 2021, Biocon Limited, an innovation-led global biopharmaceutical company, partnered with Tabuk Pharmaceutical Manufacturing Company, a leading pharmaceutical company in the Middle East and North Africa (MENA), to commercialize select specialty products in the Middle East. The products' marketing authorization will be held by Tabuk Pharmaceuticals, which will also be in charge of their registration, importation, and promotion in Saudi Arabia and other Middle Eastern nations.

On the other hand, on 29 December 2021, Novo Nordisk acquired Dicerna Pharmaceuticals. With the completion of the merger, Dicerna became a wholly-owned subsidiary of Novo Nordisk. The common stock of Dicerna will not be disclosed on listed or traded on the Nasdaq Global Select Market.

COVID-19 Impact: Positive impact on the global nicotinamide adenine dinucleotide market

The COVID-19 pandemic prompted business owners to protect and maintain their supply chains to meet the growing demand for their products. However, improvements in NAD supplements and products, along with growing knowledge of the benefits of the products, supported product deployment in the cosmetics and pharmaceutical sectors. In order to stay ahead of the competition and drive overall business growth, key market players in the nicotinamide adenine dinucleotide market spend a lot of time expanding their product portfolios and conducting extensive R&D projects. The outcomes of a clinical investigation on the security and tolerability of the NAD + precursor nicotinamide riboside was released in October 2022 by the dietary supplement expert ChromaDex (NR). The results showed that NR could increase NAD + levels, making it an innovative treatment for heart failure with a lower ejection fraction.

The global nicotinamide adenine dinucleotide market report would provide an access to approximately 53 market data tables, 43 figures and 96 pages.

Table of Contents

1. Scope and Methodology

  • 1.1. Research Methodology
  • 1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary

  • 3.1. Market Snippet by Grade
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market impacting factors
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
  • 4.2. Impact analysis

5. Industry Analysis

  • 5.1. Porter's five forces analysis
  • 5.2. Value chain analysis
  • 5.3. Patent Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives

7. By Grade

  • 7.1. Introduction
    • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Type
    • 7.1.2. Market attractiveness index, By Type
  • 7.2. Food Grade *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 7.3. Pharmaceutical Grade
  • 7.4. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By Application
    • 8.1.2. Market attractiveness index, By Application
  • 8.2. Dietary Supplements *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 8.3. Pharmaceuticals
  • 8.4. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key region-specific dynamics
    • 9.2.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Grade
    • 9.2.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. South America
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Grade
    • 9.3.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.3.5.1. Brazil
      • 9.3.5.2. Argentina
      • 9.3.5.3. Rest of South America
  • 9.4. Europe
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Grade
    • 9.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.4.5.1. Germany
      • 9.4.5.2. U.K.
      • 9.4.5.3. France
      • 9.4.5.4. Spain
      • 9.4.5.5. Italy
      • 9.4.5.6. Rest of Europe
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Grade
    • 9.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Grade
    • 9.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application

10. Competitive Landscape

  • 10.1. Competitive scenario
  • 10.2. Competitor strategy analysis
  • 10.3. Market positioning/share analysis
  • 10.4. Mergers and acquisitions analysis

11. Company Profiles

  • 11.1. Bontac Bioengineering *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Hefei Home Sunshine Pharmaceutical Technology Co., Ltd.
  • 11.3. F. Hoffmann-La Roche Ltd
  • 11.4. HiMedia Laboratories
  • 11.5. NutriScience Innovations, LLC
  • 11.6. Nutrifoods
  • 11.7. Bontac Bio-engineering(shenzhen)co., ltd
  • 11.8. Krackeler Scientific
  • 11.9. Shandong Lankang Bio-Technology Co., Ltd.
  • 11.10. Shenzhen Hygieia Biotechnology Co., Ltd
  • List not Exhaustive*

12. DataM

  • 12.1. Appendix
  • 12.2. About us and services
  • 12.3. Contact us